Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses.

ABSTRACT: Whereas systemic IL12 is associated with potentially life-threatening toxicity, intratumoral delivery of IL12 through tavokinogene telseplasmid electroporation (tavo) is safe and can induce tumor regression at distant sites. The mechanism by which these responses are mediated is unknown but is presumed to result from a cellular immune response. In a phase II clinical trial of tavo (NCT01502293), samples from 29 patients with cutaneous melanoma with in-transit disease were assessed for immune responses induced with this treatment. Within the blood circulating immune cell population, we found that the frequencies of circulating PD-1⁺ CD4⁺ and CD8⁺ T cells declined with treatment. Circulating immune responses to gp100 were also detected following treatment as

SUBMITTER: Greaney SK 

PROVIDER: S-EPMC7002232 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature